CDKN2B-AS1 (Gene)

Description:CDKN2B and CDKN2A antisense cis and trans regulatory RNA 1

This gene is located within the CDKN2B-CDKN2A gene cluster at chromosome 9p21. The gene product is a functional RNA molecule that interacts with polycomb repressive complex-1 (PRC1) and -2 (PRC2), leading to epigenetic silencing of other genes in this cluster. This region is a significant genetic susceptibility locus for cardiovascular disease, and has also been linked to a number of other pathologies, including several cancers, intracranial aneurysm, type-2 diabetes, periodontitis, Alzheimer's disease, endometriosis, frailty in the elderly, and glaucoma. Multiple alternatively processed transcript variants have been detected, some of which may take the form of circular RNA molecules (PMID:21151960). [provided by RefSeq, May 2014]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View CDKN2B-AS1's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with CDKN2B-AS1.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using CDKN2B-AS1.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for CDKN2B-AS1.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with CDKN2B-AS1.

Results found

Linked to

	Label	Description
	GSE108464 AZ-628 11 v 12 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 6 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE193993 SSTR2 knockout 5 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE108464 AZ-628 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 4 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 1 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE183535 MYC inhibition HeLa 0 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE225901 dexamethasone 2 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE164529 tamoxifen 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

GSE108464 AZ-628 11 v 12 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 3 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 6 v 7 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE193993 SSTR2 knockout 5 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE108464 AZ-628 1 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 crizotinib 4 v 9 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE195568 palbociclib 1 v 10 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE183535 MYC inhibition HeLa 0 v 6 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE225901 dexamethasone 2 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE164529 tamoxifen 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.